Cargando…

Antibody–Drug Conjugates for Cancer Therapy

Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on...

Descripción completa

Detalles Bibliográficos
Autores principales: Parslow, Adam C., Parakh, Sagun, Lee, Fook-Thean, Gan, Hui K., Scott, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344263/
https://www.ncbi.nlm.nih.gov/pubmed/28536381
http://dx.doi.org/10.3390/biomedicines4030014
_version_ 1782513503081332736
author Parslow, Adam C.
Parakh, Sagun
Lee, Fook-Thean
Gan, Hui K.
Scott, Andrew M.
author_facet Parslow, Adam C.
Parakh, Sagun
Lee, Fook-Thean
Gan, Hui K.
Scott, Andrew M.
author_sort Parslow, Adam C.
collection PubMed
description Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance.
format Online
Article
Text
id pubmed-5344263
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53442632017-05-23 Antibody–Drug Conjugates for Cancer Therapy Parslow, Adam C. Parakh, Sagun Lee, Fook-Thean Gan, Hui K. Scott, Andrew M. Biomedicines Review Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance. MDPI 2016-07-11 /pmc/articles/PMC5344263/ /pubmed/28536381 http://dx.doi.org/10.3390/biomedicines4030014 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Parslow, Adam C.
Parakh, Sagun
Lee, Fook-Thean
Gan, Hui K.
Scott, Andrew M.
Antibody–Drug Conjugates for Cancer Therapy
title Antibody–Drug Conjugates for Cancer Therapy
title_full Antibody–Drug Conjugates for Cancer Therapy
title_fullStr Antibody–Drug Conjugates for Cancer Therapy
title_full_unstemmed Antibody–Drug Conjugates for Cancer Therapy
title_short Antibody–Drug Conjugates for Cancer Therapy
title_sort antibody–drug conjugates for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344263/
https://www.ncbi.nlm.nih.gov/pubmed/28536381
http://dx.doi.org/10.3390/biomedicines4030014
work_keys_str_mv AT parslowadamc antibodydrugconjugatesforcancertherapy
AT parakhsagun antibodydrugconjugatesforcancertherapy
AT leefookthean antibodydrugconjugatesforcancertherapy
AT ganhuik antibodydrugconjugatesforcancertherapy
AT scottandrewm antibodydrugconjugatesforcancertherapy